Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bevitrol is an oral prescription digestive enzyme dietary supplement composed of **amylase, protease, and lipase** in capsule form. It is positioned for the clinical dietary management of suboptimal nutritional status and for patients who require advanced nutritional supplementation, particularly in physiologically stressful conditions and in disorders associated with impaired pancreatic enzyme production or function such as **exocrine pancreatic insufficiency, cystic fibrosis, and chronic pancreatitis**. Mechanistically, the product provides exogenous carbohydrase, protease, and lipase activity to support digestion and absorption of carbohydrates, proteins, and fats rather than acting through a discrete receptor-mediated pharmacology. The provided context describes red and white capsules containing 9,000-112,500-112,500 units of amylase-protease-lipase, typically dosed at 1 capsule daily under medical supervision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bevitrol.